Access to Pediatric Technologies Act of 2025

HR1931, referred to the Committees on Energy and Commerce and Ways and Means, aims to incentivize the development of pediatric medical devices and drugs. This legislation directly addresses a historical gap in the market where pediatric-specific treatments are often limited due to smaller market sizes and higher development costs. The bill will likely include provisions for expedited review processes, extended market exclusivity, and potentially grant funding or tax credits for companies investing in pediatric technologies. This creates a clear financial incentive for companies to prioritize pediatric research and development. Funding mechanisms for this bill will likely involve a combination of direct appropriations for research grants administered by agencies like the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), as well as tax credits for R&D expenses. Companies with existing pediatric divisions or those capable of quickly pivoting R&D efforts will be best positioned. Pharmaceutical giants like Johnson & Johnson ($JNJ), Pfizer ($PFE), and Merck ($MRK) with broad R&D capabilities will benefit. Medical device companies such as Abbott Laboratories ($ABT), GE HealthCare Technologies ($GEHC), Intuitive Surgical ($ISRG), and Medtronic ($MDT) will also see increased opportunities for pediatric-specific device development. Historically, similar legislation has spurred innovation. The Best Pharmaceuticals for Children Act (BPCA) of 2002 and the Pediatric Research Equity Act (PREA) of 2003 provided incentives for pediatric drug development. Following the passage of BPCA, the number of pediatric studies increased significantly, leading to more labeled indications for children. While direct stock market data from 2002-2003 is less granular for specific pediatric segments, the general pharmaceutical sector saw steady growth. For example, between 2002 and 2004, the S&P 500 Pharmaceuticals Index (a proxy for the sector) rose approximately 15%, indicating a positive environment for drug developers. Specific winners include large pharmaceutical companies like Johnson & Johnson ($JNJ) and Pfizer ($PFE) due to their extensive R&D budgets and existing market presence. Medical device companies such as Abbott Laboratories ($ABT) and Medtronic ($MDT) will gain from expanded market opportunities for pediatric-specific devices. Companies specializing in niche pediatric technologies will also see significant growth. There are no direct losers, but companies that fail to adapt and invest in pediatric R&D will miss out on this new market expansion. The bill is currently in committee review. The next step involves committee hearings and potential markups. If it passes committee, it will move to a floor vote in the House. Given the bipartisan nature of pediatric healthcare, the bill has a strong chance of passage within the current legislative session, likely by late 2025 or early 2026. Companies should begin assessing their pediatric R&D pipelines now to capitalize on the impending incentives.